Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...
Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthcare Conference to discuss ...
Clarivate Plc , a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact ...
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient careLONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback